MXPA02002486A - Use dexrazoxane for treating psoriasis. - Google Patents

Use dexrazoxane for treating psoriasis.

Info

Publication number
MXPA02002486A
MXPA02002486A MXPA02002486A MXPA02002486A MXPA02002486A MX PA02002486 A MXPA02002486 A MX PA02002486A MX PA02002486 A MXPA02002486 A MX PA02002486A MX PA02002486 A MXPA02002486 A MX PA02002486A MX PA02002486 A MXPA02002486 A MX PA02002486A
Authority
MX
Mexico
Prior art keywords
dexrazoxane
treating psoriasis
psoriasis
treating
dioxopiperazin
Prior art date
Application number
MXPA02002486A
Other languages
Spanish (es)
Inventor
Rogan-Grgas Jadranka
Original Assignee
Cyathus Exquirere Pharmaforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyathus Exquirere Pharmaforsch filed Critical Cyathus Exquirere Pharmaforsch
Publication of MXPA02002486A publication Critical patent/MXPA02002486A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Abstract

The use for the manufacture of a medicament for treating psoriasis of dexrazoxane, the d isomer of 1,2 bis(3,5 dioxopiperazin 1 yl) propane, or a physiologically acceptable salt thereof.
MXPA02002486A 1999-09-10 2000-09-08 Use dexrazoxane for treating psoriasis. MXPA02002486A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT155899 1999-09-10
US18380600P 2000-02-22 2000-02-22
PCT/EP2000/008879 WO2001019358A2 (en) 1999-09-10 2000-09-08 Use dexrazoxane for treating psoriasis

Publications (1)

Publication Number Publication Date
MXPA02002486A true MXPA02002486A (en) 2004-09-10

Family

ID=25596169

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02002486A MXPA02002486A (en) 1999-09-10 2000-09-08 Use dexrazoxane for treating psoriasis.

Country Status (16)

Country Link
EP (1) EP1214073A2 (en)
KR (1) KR20020035131A (en)
CN (1) CN1378451A (en)
AU (1) AU7286500A (en)
BG (1) BG106428A (en)
BR (1) BR0013921A (en)
CA (1) CA2384685A1 (en)
CZ (1) CZ2002729A3 (en)
EE (1) EE04871B1 (en)
HR (1) HRPK20020201B1 (en)
HU (1) HUP0202791A3 (en)
MX (1) MXPA02002486A (en)
PL (1) PL354980A1 (en)
RU (1) RU2002106874A (en)
SK (1) SK2802002A3 (en)
WO (1) WO2001019358A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021053523A1 (en) * 2019-09-18 2021-03-25 Tryp Therapeutics Compositions and methods to improve the therapeutic benefit of bis-dioxopiperazines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941790A (en) * 1967-07-03 1976-03-02 National Research Development Corporation Bis diketopiperazines
GB1234935A (en) * 1967-07-03 1971-06-09 Nat Res Dev Piperazine derivatives
US4963679A (en) * 1988-02-17 1990-10-16 Erbamont, Inc. Process for preparing bis (3,5-dioxopiperazinyl) alkanes or alkenes
JPH09503749A (en) * 1993-07-23 1997-04-15 エルエックスアール バイオテクノロジー インコーポレイテッド Methods of treating apoptosis and related conditions

Also Published As

Publication number Publication date
EE200200128A (en) 2003-04-15
WO2001019358A3 (en) 2001-10-04
HUP0202791A2 (en) 2003-01-28
EE04871B1 (en) 2007-08-15
CZ2002729A3 (en) 2002-07-17
HRPK20020201B1 (en) 2004-08-31
CA2384685A1 (en) 2001-03-22
BR0013921A (en) 2002-05-14
RU2002106874A (en) 2003-11-20
HRP20020201A2 (en) 2003-06-30
PL354980A1 (en) 2004-03-22
CN1378451A (en) 2002-11-06
EP1214073A2 (en) 2002-06-19
HUP0202791A3 (en) 2003-02-28
WO2001019358A2 (en) 2001-03-22
BG106428A (en) 2003-04-30
KR20020035131A (en) 2002-05-09
SK2802002A3 (en) 2003-02-04
AU7286500A (en) 2001-04-17

Similar Documents

Publication Publication Date Title
BG106586A (en) Pyrazolopyramidines as therapeutic agents
DE50008336D1 (en) MULTILAYER TABLET FOR THE ADMINISTRATION OF A FIXED COMBINATION OF TRAMADOL AND DICLOFENAC
DE60112974D1 (en) Carbolinderivate
MY118151A (en) Pharmaceutical formulations containing voriconazole.
MY126559A (en) Fungicidal 2-methoxybenzophenones
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
MX9204625A (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A MAMMAL SPECIES, WHICH SUFFERS FROM CONGESTIVE HEART DEFICIENCY.
BG105556A (en) New esters derived from substituted phenyl-cyclohexyl compounds
SE9704546D0 (en) Novel compounds
MXPA03002911A (en) Chemical compounds.
PL369999A1 (en) 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivatives or salts thereof
GEP20094818B (en) 2-methyl-thieno-benzodiaze-pine formulation
DE69841267D1 (en) Use of r-carprofen for the prevention of Alzheimer's disease
BG104038A (en) Use of specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing
GB9907571D0 (en) Compounds
HUP0202592A2 (en) Transdermal delivery of lasofoxifene
NZ515685A (en) Use of riluzole for the treatment of multiple sclerosis
MY128529A (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
MXPA02002486A (en) Use dexrazoxane for treating psoriasis.
IL158186A0 (en) Pharmaceutically active compounds and methods of use
RS51316B (en) Novel use of (r)-(-)-2-/5-(4-fluorophenyl)-3- pyridylmethylaminomethyl/-chromane and its physiologically acceptable salts
DE69426021T2 (en) Xamonelin tartrate
ATE323493T1 (en) CONTROLLED RELEASE OF ANTIDEPRESSANTS